Full Text View
Tabular View
Study Results
Related Studies
Improving Diabetes Risk Factors in Persons With Schizophrenia or Bipolar Disorder by Switching to Ziprasidone
This study has been completed.
Study NCT00538642   Information provided by The University of Texas Health Science Center at San Antonio

First Received on October 2, 2007.   Last Updated on November 27, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Schizoaffective Disorder
Bipolar Disorder
Additional conditions recognized in this trial
Psychotic Disorders
More general conditions related to this trial
Affective Disorders, Psychotic
Mental Disorders
Mood Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
ziprasidone
Additional drug interventions recognized in this trial
Antipsychotic Agents
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
The University of Texas Health Science Center at San Antonio


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services